Idelalisib

艾德拉尼

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameIdelalisib
Drug Alias NameIdelalisibum艾代拉里斯伊德利塞艾拉利司艾代拉利司 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsAmyloidosisRhinitis, AllergicWaldenstrom Macroglobulinemia +[14] 
Global Approved IndicationsLymphoma, FollicularLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2014/07/23
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland UcJiangsu Hansoh Pharmaceutical Group Co Ltd +[5] 
Inactive CompaniesDana-Farber Cancer Institute
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[7] 
Inactive IndicationsAmyloidosisRhinitis, AllergicMultiple Myeloma +[7] 

Other Information

ATC CodeL01EM01
Related LinksWikipediaDrugBankKEGG